Claims for Patent: 6,677,358

Summary for Patent: 6,677,358

Title:	NIDDM regimen
Abstract:	The present invention discloses a regimen for the treatment of type 2 diabetes, in which the endogenous secretion of insulin is stimulated in connection with meals, by administering a short-acting, oral hypoglycemic agent. Also, the present invention discloses a method of achieving improvement in glycemic control by combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.
Inventor(s):	Muller; Peter Gi.o slashed.rtz (Princeton Junction, NJ)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	09/459,526
Patent Claims:	1. A pharmaceutical composition comprising repaglinide and metformin together with a suitable carrier. 2. A pharmaceutical composition of claim 1 provided in the form of a tablet. 3. A pharmaceutical composition of claim 1 provided in the form of a capsule. 4. A method for treating non-insulin dependent diabetes mellitus (NIDDM) comprising administering to a patient in need of such treatment repaglinide in combination with metformin. 5. A kit for use in the treatment of a patient having non-insulin dependent diabetes mellitus (NIDDM), said kit comprising an amount of repaglinide formulated for administration to said patient and an amount of metformin formulated for administration to said patient.